StoryFunding
NewLimit adds $45M to its Series B
Five months after closing its Series B, NewLimit raised an additional $45M at a $1.62B valuation from new investors Eli Lilly, Duke Management, Section 32, and Abstract, with existing backers Kleiner Perkins, Dimension, Human Capital, and Boost also participating. The company attributed the round to technical breakthroughs following its Series B that position it for its first clinical study.
- $45M raised at $1.62B valuation; new investors include Eli Lilly, Duke Management, Section 32, and Abstract.
- Existing investors Kleiner Perkins, Dimension, Human Capital, and Boost participated, increasing their commitments.
- Timing reflects 'new technical breakthroughs' positioning NewLimit for clinical studies in the coming years.